SI2276486T1 - Novi substituirani imidazokinolini - Google Patents

Novi substituirani imidazokinolini

Info

Publication number
SI2276486T1
SI2276486T1 SI200930788T SI200930788T SI2276486T1 SI 2276486 T1 SI2276486 T1 SI 2276486T1 SI 200930788 T SI200930788 T SI 200930788T SI 200930788 T SI200930788 T SI 200930788T SI 2276486 T1 SI2276486 T1 SI 2276486T1
Authority
SI
Slovenia
Prior art keywords
novel substituted
substituted imidazoquinolines
imidazoquinolines
novel
substituted
Prior art date
Application number
SI200930788T
Other languages
English (en)
Inventor
Volker Gekeler
Thomas Maier
Astrid Zimmermann
Hans-Peter Hofmann
Sanjeev A. Kulkarni
Anil P. Jagtap
Ganesh S. Chaure
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of SI2276486T1 publication Critical patent/SI2276486T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200930788T 2008-03-24 2009-03-23 Novi substituirani imidazokinolini SI2276486T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN614MU2008 2008-03-24
PCT/EP2009/053399 WO2009118296A2 (en) 2008-03-24 2009-03-23 Novel substituted imidazoquinolines
EP09724784.5A EP2276486B1 (en) 2008-03-24 2009-03-23 Novel substituted imidazoquinolines

Publications (1)

Publication Number Publication Date
SI2276486T1 true SI2276486T1 (sl) 2014-01-31

Family

ID=40718842

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930788T SI2276486T1 (sl) 2008-03-24 2009-03-23 Novi substituirani imidazokinolini

Country Status (25)

Country Link
US (3) US9073913B2 (sl)
EP (2) EP2386557B1 (sl)
JP (3) JP5670876B2 (sl)
KR (1) KR101606219B1 (sl)
CN (2) CN101980707B (sl)
AU (2) AU2009228769C1 (sl)
BR (1) BRPI0909317B1 (sl)
CA (1) CA2719544C (sl)
CY (1) CY1114648T1 (sl)
DK (2) DK2276486T3 (sl)
EA (2) EA029926B1 (sl)
ES (2) ES2436540T3 (sl)
HK (1) HK1152238A1 (sl)
HR (1) HRP20131139T1 (sl)
IL (1) IL208220A (sl)
ME (1) ME02124B (sl)
MX (2) MX2010010511A (sl)
NZ (2) NZ599446A (sl)
PL (1) PL2276486T3 (sl)
PT (1) PT2276486E (sl)
RS (1) RS53059B (sl)
SG (1) SG189692A1 (sl)
SI (1) SI2276486T1 (sl)
UA (1) UA105764C2 (sl)
WO (1) WO2009118296A2 (sl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
PT2276486E (pt) * 2008-03-24 2013-12-04 4Sc Discovery Gmbh Novas imidazoquinolinas substituídas
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
DK2714071T3 (da) 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
IN2014CN02152A (sl) 2011-09-01 2015-09-04 Novartis Ag
JP2015509520A (ja) 2012-03-07 2015-03-30 ノバルティス アーゲー 狂犬病ウイルス免疫原のアジュバント化製剤
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
ES2959398T3 (es) 2013-08-28 2024-02-26 Pci Biotech As Compuesto y método para vacunación e inmunización
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN104800843B (zh) * 2015-04-02 2017-07-04 中国农业科学院兰州兽医研究所 一种用于弓形虫感染预防的药剂及应用
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
WO2017102652A1 (en) * 2015-12-14 2017-06-22 Glaxosmithkline Biologicals S.A. Pegylated imidazoquinolines as tlr7 and tlr8 agonists
SI3679025T1 (sl) 2017-09-06 2022-07-29 BioNTech SE Substituirani imidazokinolini kot agonisti TLR7
WO2019048036A1 (en) 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES
JP7197244B2 (ja) * 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物
TW202012395A (zh) 2018-04-14 2020-04-01 德商４Ｓｃ製藥公司 用於治療癌症的包含組蛋白去乙醯酶（hdac）抑制劑和tlr7 激動劑和/或tlr8 激動劑的藥物組合產品
US10906923B1 (en) * 2019-02-07 2021-02-02 Canwell Biotech Limited Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
SG11202108752YA (en) * 2019-03-07 2021-09-29 BioNTech SE Process for the preparation of a substituted imidazoquinoline
CN114599360A (zh) * 2019-10-29 2022-06-07 骏达贸易有限公司 4-氨基-咪唑并喹啉化合物及其用途
CN117736210A (zh) * 2021-01-28 2024-03-22 上海翊石医药科技有限公司 一类芳杂环类化合物及其制备方法和用途
WO2023209441A1 (en) * 2022-04-29 2023-11-02 Legochem Biosciences, Inc. Imidazo[4,5-c]pyridine derivative compounds as tlr7/8 modulators
CN115181117B (zh) * 2022-08-08 2024-05-17 中国医学科学院医学生物学研究所 一种s构型手性分子化合物及其制备方法和作为疫苗佐剂的应用
CN116731015B (zh) * 2023-05-18 2024-09-27 深圳威科森生物医药科技有限公司 咪唑并喹啉化合物及其制备方法、应用和组合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229114T2 (de) * 1991-03-01 1999-11-04 Minnesota Mining And Mfg. Co., Saint Paul 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
JPH11222432A (ja) * 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
CA2467828C (en) * 2001-11-29 2011-10-04 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
CA2517655A1 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
JP4913593B2 (ja) * 2003-08-14 2012-04-11 スリーエム イノベイティブ プロパティズ カンパニー 脂質修飾された免疫応答調整剤
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
EP1686992A4 (en) 2003-11-25 2009-11-04 3M Innovative Properties Co HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME
AU2005244260B2 (en) * 2004-04-09 2010-08-05 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
CN101426524A (zh) * 2004-04-28 2009-05-06 3M创新有限公司 用于粘膜接种疫苗的组合物和方法
US20080015184A1 (en) 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006028451A1 (en) * 2004-09-03 2006-03-16 3M Innovative Properties Company 1-amino 1-h-imidazoquinolines
JP2008538203A (ja) * 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
EP1851224A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
US20080193474A1 (en) 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
JP5247458B2 (ja) * 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
US8951528B2 (en) * 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
BRPI0811125A2 (pt) * 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolinas com propriedades imunomoduladoras
PT2276486E (pt) * 2008-03-24 2013-12-04 4Sc Discovery Gmbh Novas imidazoquinolinas substituídas

Also Published As

Publication number Publication date
DK2386557T3 (en) 2018-04-23
CY1114648T1 (el) 2016-12-14
MX344330B (es) 2016-12-13
EP2276486A2 (en) 2011-01-26
AU2014210573B2 (en) 2016-05-12
US20110245289A1 (en) 2011-10-06
EP2386557B1 (en) 2018-01-10
JP2014208704A (ja) 2014-11-06
NZ588183A (en) 2012-05-25
EA023556B1 (ru) 2016-06-30
ES2436540T3 (es) 2014-01-02
SG189692A1 (en) 2013-05-31
ME02124B (me) 2014-04-30
AU2009228769A1 (en) 2009-10-01
US9073913B2 (en) 2015-07-07
AU2009228769C1 (en) 2014-11-06
BRPI0909317B1 (pt) 2021-05-25
JP5837549B2 (ja) 2015-12-24
AU2014210573A1 (en) 2014-08-28
CN103396415B (zh) 2016-08-10
IL208220A0 (en) 2010-12-30
RS53059B (en) 2014-04-30
UA105764C2 (uk) 2014-06-25
CA2719544A1 (en) 2009-10-01
US20170029422A1 (en) 2017-02-02
CN103396415A (zh) 2013-11-20
CN101980707A (zh) 2011-02-23
JP2014043458A (ja) 2014-03-13
US9908880B2 (en) 2018-03-06
HRP20131139T1 (hr) 2014-01-03
EA201001356A1 (ru) 2011-06-30
EA029926B1 (ru) 2018-05-31
JP2011515436A (ja) 2011-05-19
ES2667054T3 (es) 2018-05-09
CN101980707B (zh) 2015-05-20
NZ599446A (en) 2013-11-29
DK2276486T3 (da) 2013-11-25
EA201590628A1 (ru) 2016-03-31
US9446040B2 (en) 2016-09-20
IL208220A (en) 2016-09-29
MX2010010511A (es) 2011-04-05
EP2386557A1 (en) 2011-11-16
WO2009118296A2 (en) 2009-10-01
WO2009118296A3 (en) 2009-12-03
AU2009228769B2 (en) 2014-07-10
PT2276486E (pt) 2013-12-04
KR101606219B1 (ko) 2016-03-24
PL2276486T3 (pl) 2014-04-30
US20150335636A1 (en) 2015-11-26
HK1152238A1 (en) 2012-02-24
JP5670876B2 (ja) 2015-02-18
EP2276486B1 (en) 2013-08-28
CA2719544C (en) 2018-01-09
BRPI0909317A2 (pt) 2017-04-11
KR20100134060A (ko) 2010-12-22

Similar Documents

Publication Publication Date Title
ME02124B (me) Novi supstituisani imidazohinolini
HK1256310A1 (zh) N-磺酰基吡咯衍生物
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
EP2376494A4 (en) DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
PL2308877T3 (pl) Pochodne imidazopirydyn-2-onu
IL208990A0 (en) Novel phenylimidazopyrazines
EP2331543A4 (en) 3-DÉSAZANEPLANOCINE DERIVATIVES
IL210406A0 (en) Pyrrolopyridinylpyrimidin - 2 - ylamine derivatives
IL231955B (en) Tetracycline compounds are substituted at the 7c position with fluorine
EP2291078A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
EP2279532A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
IL210869A0 (en) Imidazothiadiazoles derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210613A0 (en) Novel acylaminobenzamide derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
IL208281A0 (en) Substituted cyclohexyldiamines
IL213424A0 (en) Quinazolinamide derivatives
IL208548A0 (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
IL209175A0 (en) Substituted qunazolines
EP2341909A4 (en) NEW SUBSTITUTED AZABENZOXAZOLE
EP2292613A4 (en) DIHYDROINDOLINONDERIVATE
EP2332925A4 (en) NOVEL DIHYDROTRIAZINE DERIVATIVE